Precision medicine enhances prostate cancer treatment with genetic profiling

Second-generation hormone drugs should be the first treatment for men with metastatic castration-resistant prostate cancer, over chemotherapy, according to Swedish researchers. The study from the Karolinska Institutet found that these hormone drugs, which inhibit the androgen receptor, offer improved response to treatment and a longer life expectancy. Outcomes vary depending on tumour mutations, highlighting the importance of precision medicine based on individuals’ genetic profiles.